Skip to main content

Table 1 Participant demographics and clinical pathological results

From: Early assessment of shear wave elastography parameters foresees the response to neoadjuvant chemotherapy in patients with invasive breast cancer

Parameters Responder (n = 34) Non-responder (n = 28) p value
Age at enrollment (years)a 52.8 ± 11.3 53.1 ± 16.3 0.72
Pathologic type 0.03*
 Invasive ductal carcinoma 29 (63.0) 17 (37.0)  
 Invasive lobular carcinoma 4 (50.0) 4 (50.0)  
 Invasive mammary carcinoma with mixed ductal and lobular features 1 (12.5) 7 (87.5)  
Pathologic grade 0.05
 I/II 11 (39.3) 17 (60.7)  
 III 23 (67.7) 11 (32.3)  
Estrogen receptor status 0.17
 Positive 20 (47.6) 22 (52.4)  
 Negative 14 (70.0) 6 (30.0)  
Progesterone receptor status 0.44
 Positive 20 (50.0) 20 (50.0)  
 Negative 14 (63.6) 8 (36.4)  
HER2 status 0.19
 Positive 15 (68.2) 7 (31.8)  
 Negative 19 (47.5) 21 (52.5)  
Ki-67 index (%)  
 Measureda 40.1 ± 25.1 (46.7) 27.0 ± 20.1 (53.3) 0.05
 Data missing (76.5) (23.5)  
Subtype
 ER+ tumor types    0.03*
 Luminal A 1 (12.5) 7 (87.5)  
 Luminal B (HER2-) 8 (47.1) 9 (52.9)  
 Luminal B (HER2+) 11 (68.8) 5 (31.2)  
 Other tumor types    0.92
 HER2+ 4 (66.7) 2 (33.3)  
 TN 9 (81.8) 2 (18.2)  
 Data missing 1 (25.0) 3 (75.0)  
  1. Data in parentheses are percentages
  2. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, TN triple-negative
  3. aData are mean ± standard deviation
  4. *p < 0.05; the difference is statistically significant